Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Amgen gets rights to Kyowa's KW0761 for inflammation; terminated

Executive Summary

Amgen has licensed exclusive global development and marketing rights to Kyowa Hakko Kogyo's (in the process of merging with Kirin) KW0761 humanized monoclonal antibody. The deal excludes Japan, Korea, China, and Taiwan.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register